LivaNova PLC (LIVN) Stock
NSQ · LIVN
78.01
Fundamentals
Market cap
$4.30B
Price / Earnings ratio
22.7x
Price / Sales ratio
2.9x
Price / Book ratio
3.2x
Return on assets
0.0%
Ex-Dividend date
N/A
Last payment date
N/A
Dividend amount
$0.00
Dividend yield
0.0%
Debt / Equity ratio
N/A
Latest news
About LivaNova PLC
UK-based LivaNova was born of a combination of Cyberonics in the US and Sorin in Italy. The medical-device firm is primarily focused on cardiopulmonary solutions (with heart-lung machines and oxygenation equipment) as well as neuromodulation devices for treatment-resistant epilepsy and depression. Following the merger, LivaNova divested its cardiac rhythm management, heart valve, and extracorporeal membrane oxygenation businesses. It derives roughly half of its revenue from the US market, another 21% from Europe, and the remainder from the rest of the world.
SectorHealthcare
IndustryMedical Devices
Employees3,300
CEOMr. Vladimir A. Makatsaria
IPO DateFeb 10, 1993
HeadquartersGloucester, United Kingdom
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Vladimir A. Makatsaria | CEO & Director | 1973 |
| Mr. Alex Shvartsburg C.M.A. | Chief Financial Officer | 1970 |
| Ms. Natalia Sergeyevna Kozmina | Chief Human Resources Officer | 1971 |
| Mr. Ahmet Tezel Ph.D. | Chief Innovation Officer | 1975 |
| Ms. Lindsey Little | VP & Chief Accounting Officer | — |
| Briana Gotlin | Vice President of Investor Relations | — |
| Ms. Anne M. Liddy | Chief Legal Officer | 1976 |
| Deanna Wilke | Vice President of Corporate Communications | — |
| Mr. Philip Kowalczyk | Chief Strategy & Corporate Development Officer | — |
| Mr. Paul R. Buckman | President of Advanced Circulatory Support & GM of Transcatheter Mitral Valve Replacement | 1956 |
Fundamentals
Valuation
Market cap$4.30B
Price-to-sales ratio2.91
Price-to-book value3.23
Price-earnings ratio22.70
Return on Equity9.00%
Return on Sales0.12%
Return on Assets0.04%
PEG ratio0.93
Earnings Per Share
Earnings Per Share$3.44
Income Statement
Average volume578,907
EBITDA$226.97M
1 year high (52w)$85.76
1 year low (52w)$48.82
Dividend
Ex dividend dateN/A
Dividend amount$0.00
Dividend yield0.00%
Last payment dateN/A
Dividend yield (TTM)N/A
Next earnings reportN/A
Solvency
Debt-to-equity ratioN/A



